"10.1371_journal.pone.0040166","plos one","2012-07-05T00:00:00Z","Irene M Lelieveld; Martijn L T M MÃ¼ller; Nicolaas I Bohnen; Robert A Koeppe; Ronald D Chervin; Kirk A Frey; Roger L Albin","Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, The Netherlands; Department of Radiology, University of Michigan, Ann Arbor, Michigan, United States of America; Department of Neurology, University of Michigan, Ann Arbor, Michigan, United States of America; Geriatrics Research, Education, and Clinical Center, VAAAHS, Ann Arbor, Michigan, United States of America; Sleep Disorders Center, University of Michigan, Ann Arbor, Michigan, United States of America","Conceived and designed the experiments: RLA NIB KAF. Performed the experiments: IML MLTMM RAK. Analyzed the data: IML MLTMM RAK RDC. Wrote the paper: ILM MLTMM RLA.","Dr. Chervin is or has been a member of the board or advisory board of Sweet Dreamzzz, Inc, and Pavad Medical. He has served as a consultant for Arena Pharmaceuticals, Inc., Guidepoint Global, Inc., OrbiMed Advisors, LLC, Proctor & Gamble, and Zansors. He has received gifts to support education from Philips Respironics and Fisher Paykel. He served as a data and safety monitor for the TURBO trial that involved surgical intervention in patients with sleep apnea, and he serves on the data and safety monitoring board for a trial by Cereve of a device to treat insomnia. Dr. Chervin is a section editor for UpToDate. Dr. Koeppe is a consultant for Johnson & Johnson, and Merck. Dr. Frey has investment (equity) holdings in General Electric, Novo Nordisk, Merck, Bristol-Myers-Squibb, and Medtronic. He receives research support from GE Healthcare and Avid Pharmaceuticals. He serves on the Journal of Nuclear Medicine - Associate Editor for CE Quarterly Journal of Nuclear Medicine. He consulted for GE healthcare, Avid Pharmaceuticals, and Bayer-Schering Pharmaceuticals. Dr. Albin has received compensation for expert witness testimony in litigation regarding dopamine agonist induced impulse control disorders. Dr. Albin serves on the editorial boards of Neurology, Experimental Neurology, and Neurobiology of Disease. Dr. Albin served on the Data Safety and Monitoring Boards for the QE3 and HORIZON trials. There are no patents, products in development, or marketed products to declare. This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials.","2012","07","Irene M Lelieveld","IML",7,TRUE,3,3,4,3,TRUE,TRUE,FALSE,0,NA,FALSE
